Correct answerD. Royalty paid in installments for the purchase of rights to manufacture and sell patient medicines.
Explanation
Paying for the rights to manufacture and sell a product acquires a long-lasting intangible asset, so it is capital expenditure even when paid in instalments, unlike compensation, gratuities or trade mark renewal fees.
Discussion